Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 4 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Triple superior to quadruple combination ART for treatment-naïve people with HIV

Stephen Padilla
19 Jul 2019

A quadruple combination antiretroviral therapy (cART) demonstrates similar effects when compared to a triple cART in treatment-naïve people with HIV, according to the results of a systematic review and meta-analysis.

“This finding lends support to current guidelines recommending triple cART as first-line treatment, especially considering the financial and pill burden and consequent issues introduced by a fourth drug,” researchers said.

Randomized controlled trials (RCTs) were searched in PubMed, Embase, Central, Web of Science and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016. PubMed and Embase were accessed again up to June 2018 for an updated search. Reference lists of eligible studies and related reviews were also searched.

RCTs that compared quadruple with triple cART in treatment-naïve people with HIV and evaluated at least one effectiveness or safety outcome were included. Outcomes of interest were as follows: HIV-1 RNA, CD3 T cell count, virological failure, new AIDS defining events, death and severe adverse effects. Random effects meta-analyses were performed.

Twelve RCTs, including 4,251 people with HIV, met the inclusion criteria. The effects of quadruple cART on all relevant effectiveness and safety outcomes were comparable with those of triple cART, with no point estimates favouring quadruple therapy. [BMJ 2019;366:l4179]

The risk ratio relative to the triple cART was 0.99 (95 percent CI, 0.93–1.05) for undetectable HIV-1 RNA, 1.00 (0.90–1.11) for virological failure, 1.17 (0.84–1.63) for new AIDS defining events, 1.23 (0.74–2.05) for death, and 1.09 (0.89–1.33) for severe adverse effects. The mean difference in CD4 T cell count increase was –19.55 cells/μL (–43.02 to 3.92) between the two treatment arms.

“In general, the results were similar, regardless of the specific regimens of combination antiretroviral therapies, and were robust in all subgroup and sensitivity analyses,” researchers said.

Subgroup analyses showed that different drug combinations would not necessarily result in a big difference between quadruple and triple cART even as their combinations could contribute to the effects of the two regimen types themselves. [BMJ 2002;324:757; Lancet HIV 2016;3:e510-e520]

Moreover, the addition of a fourth drug to first-line treatment increases financial and pill burden, potentially leading to a reduced medication adherence and, consequently, drug resistance and treatment failure. It may also limit drug options for second-line treatment and beyond, according to researchers. [Clin Infect Dis 2003;37:1112-1118; Infect Disord Drug Targets 2011;11:167-174]

It could be thus concluded that triple cART is superior to quadruple cART and that current guidelines recommending triple therapy as first-line treatment remain relevant, they added. [JAMA 2014;312:410-425; www.who.int/hiv/pub/arv/arv-2016/en/; www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html; www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf]

“As the chance that quadruple cART turns out to be more favourable than triple cART is low, the idea of evidence-based research deserves more emphasis in proposing further trials on this topic,” researchers said. “However, this study does not exclude the possibility that quadruple cART would be better than triple ones when new classes of antiretroviral drugs are made available.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 4 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).